There is no single best treatment for vasculitis because the condition comes in many forms, each affecting different blood vessels and organs. But the core strategy is consistent: suppress the immune system’s attack on blood vessel walls, bring the disease into remission, then keep it there with gentler long-term therapy. For the most common serious forms, this means a combination of steroids and a powerful immune-suppressing medication, followed by 18 to 24 months (or longer) of maintenance treatment.
How Treatment Is Structured
Vasculitis treatment happens in two phases. The first, called induction, uses aggressive therapy to stop the inflammation quickly. The second, called maintenance, uses milder medications to prevent the disease from coming back. Skipping or shortening maintenance is risky: 30 to 50% of patients with the most common small-vessel forms relapse within five years even with treatment, and stopping early makes that more likely.
The specific medications depend on which type of vasculitis you have, which organs are affected, and how severe the disease is at diagnosis.
Small-Vessel Vasculitis (ANCA-Associated)
The most widely studied and treated forms of vasculitis are the ANCA-associated types, which primarily affect small blood vessels in the kidneys, lungs, and sinuses. Current guidelines recommend starting with high-dose steroids combined with either rituximab (an infusion that depletes certain immune cells) or cyclophosphamide (a traditional chemotherapy-derived immunosuppressant).
Both options achieve remission in roughly similar proportions of newly diagnosed patients. In one major trial, 64% of patients on rituximab reached remission without steroids at six months compared to 53% on cyclophosphamide. For people experiencing a relapse rather than a first episode, rituximab performed significantly better: 67% versus 42%. Because of this, and because rituximab generally has a more manageable side-effect profile, it has become the preferred first choice for many specialists, particularly for relapsing disease.
Once remission is achieved, maintenance therapy continues for at least 18 to 24 months. The recommended options are either periodic rituximab infusions or daily azathioprine with low-dose steroids. Methotrexate is another option; a head-to-head trial found it and azathioprine performed similarly for maintaining remission, with comparable rates of side effects.
Reducing Steroid Side Effects
High-dose steroids (typically starting around 1 mg per kilogram of body weight daily for the first month, then gradually tapered) are effective but come with well-known problems: weight gain, bone thinning, elevated blood sugar, mood changes, and increased infection risk. A newer medication called avacopan, which blocks a specific inflammatory signal rather than broadly suppressing the immune system, can replace steroids in ANCA-associated vasculitis. In a large trial published in the New England Journal of Medicine, avacopan matched steroids for achieving remission at six months (72% vs. 70%) and was actually superior for sustained remission at one year (66% vs. 55%). Patients on avacopan also experienced fewer steroid-related side effects.
Giant Cell Arteritis
Giant cell arteritis affects large blood vessels, most often the arteries in the head and the aorta, and typically strikes people over 50. High-dose steroids remain the first-line treatment and work quickly to relieve symptoms like severe headaches, scalp tenderness, and jaw pain. The challenge is that many patients need steroids for a year or more, and the tapering process frequently triggers relapses.
Tocilizumab, an injection that blocks an inflammatory protein called IL-6, has changed the outlook considerably. In a real-world comparison across two medical centers, 64.5% of patients receiving tocilizumab achieved steroid-free remission within 12 months, compared to just 11.1% of those on methotrexate alone. Some patients on tocilizumab were off steroids entirely by six months. This medication is now a standard addition for patients who relapse during steroid tapering or who are at high risk for steroid-related complications.
Severe and Life-Threatening Cases
When vasculitis has already caused significant kidney damage or lung bleeding, treatment becomes more aggressive. If kidney function is severely reduced, the combination of both rituximab and cyclophosphamide together (rather than choosing one) may be used alongside steroids, since data on rituximab alone in this setting is limited.
Plasma exchange, a procedure that filters harmful antibodies from the blood, was previously recommended for severe kidney involvement and lung hemorrhage. However, the large PEXIVAS trial found no meaningful benefit for reducing death or kidney failure. Current practice has largely moved away from routine plasma exchange, though some centers still consider it on a case-by-case basis for life-threatening lung bleeding.
Protecting Yourself During Treatment
Immunosuppressive therapy makes your body more vulnerable to infections that healthy immune systems easily handle. One particular concern is a type of pneumonia caused by the fungus Pneumocystis jirovecii, which can be serious in immunosuppressed patients. European guidelines recommend preventive antibiotics when steroid doses exceed roughly 15 to 30 mg daily for more than two to four weeks, especially when combined with other immune-suppressing drugs.
Your treatment team will also monitor blood work regularly. Inflammatory markers like CRP and ESR, along with ANCA antibody levels, can signal a brewing relapse, though their predictive value is imperfect. Patients with one type of ANCA antibody (anti-PR3) tend to relapse more frequently than those with another type (anti-MPO), which can influence how long your doctor recommends continuing maintenance therapy.
What Remission Actually Looks Like
Remission in vasculitis means the active inflammation has stopped, not that the disease is cured. Most people feel dramatically better within weeks of starting treatment, but the medications continue long after symptoms resolve. A typical timeline involves one to three months of intensive induction therapy, followed by a gradual steroid taper over several months, and then ongoing maintenance for at least 18 to 24 months. Some patients stay on low-dose maintenance indefinitely, particularly if they’ve relapsed before.
The 30 to 50% five-year relapse rate means that even after successful treatment, regular follow-up appointments and blood work remain part of life. Relapses are generally treatable with the same approaches used initially, though repeated courses of cyclophosphamide carry cumulative risks, which is one reason rituximab has become preferred for both induction and maintenance in patients who relapse.